Responsiveness to Full-Dose Afatinib in a Patient With Lung Adenocarcinoma Harboring EGFR S768I and V769L Mutations

J Thorac Oncol. 2019 Feb;14(2):e25-e27. doi: 10.1016/j.jtho.2018.10.165.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Afatinib / therapeutic use*
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Mutation
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors